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Calcium Phosphate Cements in 
Tissue Engineering
Manuel Pedro Fernandes Graça and Sílvia Rodrigues Gavinho
Abstract
Calcium phosphate cements (CPCs) consist of a combination of calcium phos-
phates and a liquid phase, allowing it to fit into the body where it was inserted. 
Several chemical compositions have been synthesized, promoting specific 
characteristics to the cements for applications such as bone augmentation and 
reinforcement and metal implant fixation. The hardening reaction mechanism is at 
low temperatures and makes it capable of incorporating different drugs and other 
biological molecules. In addition to the abovementioned advantages, CPCs have 
excellent bioactivity and osteoconductivity and the ability to form a bone bond. 
Its function as osteoconductor can be improved by insertion of growth factors. In 
addition, it is possible to functionalize it with silver ions and use it as a coating of 
implants, conferring antibacterial properties. In this chapter the physical, mechani-
cal, chemical, and biological properties and the possibility of using these cements as 
drug carriers or biomolecules will be discussed.
Keywords: calcium phosphates, bone cements, tissue regeneration, drug delivery, 
osseointegration, antibacterial properties
1. Calcium phosphate cements
Calcium phosphate cements (CPCs) were proposed by Brown and Chow [1] and 
LeGeros et al. [2] in the 1980s. In 1990, the first CPC was used commercially in the 
treatment of maxillofacial defects and fractures [3–5].
CPCs consist of a combination of one or more calcium orthophosphate powders 
in which a liquid phase, usually water or an aqueous solution, is added, allowing it 
to be set and hardened at the site of the body where it was implanted. This type of 
cement hardens through a dissolution reaction and a precipitation process, distin-
guishing itself from other cements that harden through a polymerization reaction. 
Over time, new compositions have been synthesized promoting specific characteris-
tics to the cements for various applications such as bone augmentation and strength-
ening [6–14], fixation of metal implants [15, 16], and vertebral fractures [17–19].
The CPCs have the essential advantage of hardening in vivo through a low-
temperature reaction. After mixing, the material becomes moldable, and its 
noninvasive injection represents an important advantage over conventional calcium 
phosphate ceramics. The fact that this type of cement does not present an exother-
mic reaction also makes it able to incorporate different drugs and other biological 
molecules, allowing its application in treatments by drug delivery [20]. In addition 
to the aforementioned advantages, CPCs have excellent bioactivity and osteocon-
ductivity and an excellent ability to form a bone bond. Its rate of resorption is also 
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a factor to take into account, since, after modifying its structure, it is possible to 
modify that rate. Calcium phosphate cements also have disadvantages, namely, their 
low mechanical performance, which limits their application in bearing situations. 
Its intrinsic porosity also leads to this material presenting less strength compared to 
calcium phosphate ceramics [21, 22].
The cements tend to dissolve in order to achieve a stable and less soluble phase, 
the dissolution being controlled by the pH of the medium. The cements based 
on hydroxyapatite or brushite are the only final reaction products because they 
are the most stable at pH > 4.2 and pH < 4.2, respectively, even though there are 
a large number of formulations. In addition, and because these materials are 
intended to be used as bone substitutes, it is important to take into account that 
the values of the compressive strength of the cortical bone vary between 90 and 
209 MPa, [23, 24] and the spongy bone varies between 1.5 and 45 MPa. [25]. As 
reference values, the compressive strength of apatite cements usually ranges from 
20 to 50 MPa [26–32]. Brushite CPCs are generally weaker than apatite CPCs being 
around 25 MPa [33].
In summary, the main characteristics of this type of cement are presented  
in Table 1.
1.1 Physical and mechanical properties
The mechanical properties are the main properties to take into account when 
developing a biomaterial to apply surgically. The microstructural characteristics 
(porosity, quantity, size, morphology, and distribution of the crystals formed) of a 
biomaterial are the determining factor to define the mechanical properties. These 
characteristics are controlled by the synthesis process and its intrinsic parameters. 
In addition, all factors, such as chemical composition of cement, relative propor-
tions of reactants, powder or liquid additives acting as accelerators or retarders, 
particle size, liquid-powder ratio (L/P ratio) (Figure 1), applied pressure during 
synthesis, and aging conditions, will affect its mechanical properties [36].
Unlike bioceramics, which require sintering at high temperatures, CPCs are 
formed through a dissolution-precipitation process at room or body temperature. 
During this process, a crystalline matrix is formed in which with the passage of time 
and matrix it becomes increasingly dense until reaching the maximum mechanical 
properties [36].
Normally, microporosity ranges between 30 and 55% and is dependent on the 
L/P ratio; the higher this ratio is, the greater the microporosity [37].
Calcium phosphate properties
Material type Ceramic
Liquid phase Water or aqueous solutions
Powder component Calcium phosphate powders
Setting reaction mechanism Dissolutions and precipitation reaction
Reaction products Calcium phosphates, usually hydroxyapatite or brushite (37°C)
Stability Resorbable (low or high resorption rate depending on composition 
and microstructure)
Bioactivity Bioactive
Applications Bone regeneration; non-load-bearing applications
Table 1. 
The nature and properties of calcium phosphate bone cements (adapted from [34]).
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Although porosity is a disadvantage to be applied in load situations, porosity is 
sought to improve the resorbability of the material and the extent of bioactivity, 
increasing the surface area available for reaction. The presence of a certain level of 
porosity makes this material a good carrier for controlled drug systems [34].
It is possible to promote the creation of macropores in CPCs through two tech-
niques. The leaching of porogen after the adjustment creates macropores; however, 
it is necessary to add large amounts of porogen, which may compromise the injec-
tion process [37–47]. The formation of the pores can also be achieved by the forma-
tion of gas foam prior to fixation, but the release of the gas after the introduction of 
the implant may be harmful to the organism [46, 48–52]. In order to overcome the 
drawbacks of the techniques mentioned above for obtaining macroporous struc-
tures of CPCs, Ginebra et al. proposed the use of self-adjusting injectable macropo-
rous foams composed of a protein-based foaming agent and CPC paste [52].
Regardless of the composition of CPC (apatite or brushite), the strength 
decreases globally with increased porosity, which is a common occurrence in several 
materials mainly in porous materials used in bone replacement [36]. In addition to 
the pore fraction effect, pore size also significantly affects the strength of CPCs. Bai 
et al. [53] found that the compressive strength is inversely proportional to the size 
of the macropores through a study in materials with equivalent total porosity but 
with different sizes of macropores. Through Griffith’s classical theory [36], which 
relates strength to the critical size of the fault, macropores can be considered as fail-
ures, thus reducing strength. In addition to the quantity and size of the pores, the 
characteristics of the crystals (quantity, size, morphology, and distribution) also 
influence the strength of these cements. The growth of the crystals depends on the 
kinetics of the dissolution-precipitation reaction of the cement, being controlled 
by many factors. The smaller the particle size of the starting materials, the faster 
the material will be converted to apatite, and the crystals formed will not have time 
to grow. The small size of these crystals will lead to a more dense and crystalline 
organization, increasing the strength of the cement [54].
One of the conditions that influence the kinetics of apatite formation is aging. 
The transformation of the initial reactants into apatite becomes faster at higher 
Figure 1. 
Microstructure and porosity of CPCs according to particle size and L/P ratio. (A) When the particle size is small, 
there is an increase in the specific surface area, resulting in the degree of supersaturation. This phenomenon favors 
the nucleation of crystals and leads to the formation of large quantities of small needle-like crystals. When the 
particles are larger, the formation of larger plate crystals occurs. Small pores are formed in the cement where 
small particles are used. (B) Porosity and pore size distribution also vary with the L/P ratio. When the L/P ratio 
is low, the space between the particles in the mixture decreases, leading to a more compact structure of crystal 
agglomerates. In contrast, when the L/P ratio increases, the total porosity of the cement increases, and the larger 
pores are formed due to the increased separation between the aggregates (adapted from [35]).
Biological Role of Phosphorus
4
temperatures, thus making the structure more homogeneous and denser, making 
it more resistant. In contrast, high temperatures also cause the development of 
precipitated apatite crystals more rapidly, resulting in larger crystals, which will 
negatively influence the resistance [55].
The fixation kinetics may be influenced by the presence of accelerating or 
retarding substances which are added to the mixture and is an important factor in 
determining the strength of the structure.
Bermudez et al. [56] and Yang et al. [57] found that by adding certain amounts 
of apatite, the hardening time of the CPCs is lower, and the compressive strength 
increases considerably. α-Hydroxylic acids (citric acid or glycolic acid) and their 
salts (sodium citrate) are also used as retarders. The addition of the same allows to 
mix and to process more easily, reducing the L/P ratio associated with a decrease 
of the porosity, improving the strength [58–64]. However, it is necessary to take 
into account an optimum concentration of these additives since the excess may 
lead to the opposite effect and decrease the force [63]. In summary, the mechanical 
properties of the CPCs, and in particular the resistance, depend strongly on the 
microstructure, which is related to the synthesis process, chemical composition, 
powder or liquid additives acting as accelerators or retarders, particle size, L/P 
ratio, and aging conditions. In addition, it has been found that crystalline structures 
have, with smaller crystals, become more compact and homogeneous and appear to 
give better mechanical properties than those with larger crystals.
Strength has been the main property to be studied when evaluating mechanical 
performance; however, the CPCs applied in bone defects are also subject to cyclic 
loading, and the resistance of CPC to fractures cannot be evaluated by strength 
alone. In order to adequately evaluate the ability to resist fractures, it is also neces-
sary to take into account fracture toughness that describes the strength of a material 
containing cracks or notches to resist crack propagation [65, 66].
The toughness of a material depends on its nano-/microstructure and on the 
possibility of promoting the hardening activation mechanism [67, 68]. Without the 
activation of significant hardening mechanisms, the fracture toughness of CPCs is 
very low. Due to the low values of toughness, CPCs are very sensitive to defects and 
failures. The reliability, that is, the likelihood of failure of brittle materials, is also 
an important factor when one thinks of applying the cement to load-bearing sites. 
As previously mentioned, it is possible to improve the hardening mechanism by 
decreasing porosity, as it is the most damaging factor in mechanical performance. 
To overcome this problem, it is necessary to decrease the volumetric fraction of the 
pores in order to achieve a more dense matrix by compacting the cement paste prior 
to hydration.
Studies have shown that compaction pressure would significantly increase 
tensile strength [69]. However, when the compaction pressure is above 100 MPa, 
only a slight decrease in porosity is achieved, and the diametral tensile strength is 
not substantially improved.
In addition, the use of this method to promote the hardening has the same 
function of decreasing the L/P ratio, which would influence the workability and 
injectability of cement pastes, which may exclude the application of this cement in 
minimally invasive surgery.
In order to overcome this disadvantage, researchers added certain amounts of 
citric acid to the cement liquid to evaluate its effect on the fixability and fixation 
properties of apatite cements and found that this addition effectively improves the 
mechanical properties of the cement. According to this prominent effect of citric 
acid on strength improvement, Barralet et al. [61] and Gbureck et al. [60] added 
sodium citrate and compacted the resulting cement slurry, obtaining compressive 
strengths near the resistance of the cortical bone, that this composition can be used 
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in load-bearing locations. This resistance can also be achieved by other factors, 
especially in the use of citric acid but without applying external pressure, varying 
the particle size and distribution of powdered reagents [70].
1.2 Chemical and biological properties
The main chemical reaction occurring in the setting mechanism is similar in 
all these systems of cements and can be understood by analyzing the behavior of 
the solubility of the existing compounds in the composition [71–73]. During the 
fixation reaction, the two mechanisms present are dissolution and reprecipitation 
[23]. The dissolution is activated by the release of the calcium and phosphate ions 
from the starting materials, leading to supersaturation in the solution. After the 
ionic concentration reaches a critical value, the nucleation of the new phase occurs, 
usually around the powder particles. This new phase develops in line with the dis-
solution of the reactants [74].
In the dissolution/reprecipitation mechanism, the formation of the precipitates 
depends on the relative stability of the various calcium phosphate salts in the system. 
The existence of a precipitate that grows in the form of the crystal agglomerates 
determines the force that a cement can acquire [74]. The solubility phase diagram 
predicts this reaction, describing the evolution of the solubility of a compound 
through the logarithm of the total concentration of calcium (or phosphate) as a 
function of pH [71–73].
The less stable phase of calcium phosphate tends to dissolve to form a more 
stable and less soluble phase.
As mentioned above, apatite is the most stable calcium phosphate (less soluble at a 
pH above 4.2 at room temperature), and brushite is most stable at a pH below 4.2 [71].
In these reactions the amount of water consumed is nonexistent, or almost nil, 
being necessary only for the reagents to become viable and to allow homogeneity in the 
solution. For this reason, water becomes one of the main contributions to the develop-
ment of porosity in cement, and, therefore, CPCs are intrinsically porous materials.
In addition to this material, in situ, the body temperature allows its molding 
after mixing, to be injectable and therefore to be used as a carrier for biological 
drugs or molecules [75–77].
In the industry, the biological responses of materials have been increasingly 
a property to be taken into account, focusing on improving cell and tissue CPC 
interactions, as well as their applications in bone tissue engineering [78–82]. The 
improvement of these interactions is one important factor for the application of 
biomaterials and their commercialization for clinical applications.
Studies evaluating the in vivo behavior of CPCs show high levels of biocompat-
ibility and osteoconductivity, stimulating tissue regeneration [5, 82–92]. Most 
apatite cements are reabsorbed by cell-mediated mechanisms. The function of the 
osteoclastic cells in this process is to degrade the materials layer by layer, starting 
from the surface which is in contact with the bone to the nucleus. The biodegradabil-
ity of apatite CPCs is slow but higher than that of the synthesized hydroxyapatite. As 
noted above, the rate of degradation of apatite cements is controlled by precipitated 
hydroxyapatite (PHA) crystallinity, specific surface area, and matrix porosity.
The cements based on brushite have a higher reabsorption rate than apatites due 
to their superior stability in the biological environment [89–91]. However, there is a 
possibility in vivo of brushite cements to be transformed into PHA and thus reduce 
their total degradation rate. In order to retard this reaction or to avoid magnesium 
salts have been added [92].
At a biological level, the mechanism of dissolution is mediated by the action of 
physiological solutions or by cell-mediated processes (phagocytosis) [93]. Bone 
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replacement depends on the age, sex, and general metabolic health of the host and 
the site and volume where it is applied, porosity, crystallinity, chemical composition, 
particle size, and L/P ratio of the cement. Considering these factors, it can take from 
3 to 36 months for the cement to be completely reabsorbed and replaced with bone. 
However, further studies are needed to confirm the total resorption of the mate-
rial in order to be applied clinically [94]. Studies have revealed bone development 
around calcium phosphate cements, demonstrating osteoconductive and osteo-
inductive characteristics in several cases. It has been shown that within 2 weeks, 
spicules of living bone with normal bone marrow and gaps in osteocytes can be iden-
tified in the cement. After 8 weeks, the cement is almost completely surrounded by 
new bone. At this stage, no cement reabsorption is typically observed [94]. Figure 2 
shows a progressive resorption of the calcium phosphate cement matrix, with 
tricalcium phosphate (TCP) granules embedded in a matrix of dicalcium phosphate 
dihydrate (DCPD) and parallel new bone formation, in a drill hole. After 2 weeks 
almost the entire surface of the cement was in direct contact with the margins of the 
bone defect. After 4 weeks, occasional granules of β-TCP and the newly formed bone 
islets are visible. This area expanded after 6 weeks, involving a progressive reabsorp-
tion of the cement matrix and parallel neoformed formation [81].
2. Principal calcium phosphate cements
2.1 Apatite cements
The importance given in the use of apatites in bone replacement is due to the 
fact that this mineral is the base of the main inorganic part of hard tissues. In fact, 
nonstoichiometric or calcium-deficient hydroxyapatite (CDHA) is the main mineral 
phase characteristic of human bones [94]. The CPCs consist of a network of calcium 
phosphate crystals, with chemical composition and crystal size that can be modified 
to approximate the biological hydroxyapatite that exists in the living bone [95, 96].
In this regard, it is necessary to clarify that even though the stoichiometric 
hydroxyapatite has a fixed composition, the apatite structure may exist in a variety of 
compositions. CDHA comprises in its composition the possibility of varying amounts 
of calcium, where it is possible to present a completely deficient structure based on 
this base element. The composition may be expressed as Ca10 − x(HPO4)(PO4)6 
− x(OH)2 − x, where x ranges from 0 to 1, 0 for stoichiometric hydroxyapatite and 
1 for hydroxyapatite totally deficient in calcium. Biological apatite is deficient in cal-
cium containing various ionic substitutions such as Na+, K+, Mg2+, F−, and Cl− [34].
Apatite cements may form PHA or CDHA through a precipitation reaction. 
The synthesis of these cements allows the incorporation of different ions in their 
composition, depending on the initial compounds. The formation of hydroxyapa-
tite that occurs in the cement is compared to the process of formation of new bone 
Figure 2. 
Image of the drill hole with progressive resorption of the calcium phosphate cement matrix, during 8 weeks [81].
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and is also seen as a biomimetic process, because it occurs at body temperature 
and physiological environment. This may explain the fact that the hydroxyapatite 
formed in the reactions of calcium phosphate cements is much more similar to bio-
logical apatites than the ceramic hydroxyapatite resulting from high-temperature 
sintering processes [34].
The CPCs lead to the formation of PHA or CDHA and can be divided into three 
systems (single compound, two compounds, more than two compounds), taking 
into account the number and type of calcium phosphates used in the synthesis [97].
Monocomponent CPCs are those having a single calcium phosphate reagent that 
hydrolyzes to form PHA or CDHA. Taking into account that at pH 4.2 the hydroxy-
apatite is less soluble, any other calcium phosphate present will dissolve, and the 
PHA will tend to precipitate. However, when the formation of PHA occurs, from 
the hydrolysis of calcium phosphate, the reaction mechanism becomes very slow, 
due to a decrease in the level of supersaturation, as the reaction proceeds [13]. In 
this in which only one compound is present, no release of any acid or no base occurs 
due to the Ca and P ratio being maintained [34, 35].
The second type of cement that may exist is composed of two calcium phos-
phates, one acid and the other basic, where they adjust after an acid–base reaction. 
The most commonly used compound is usually tetracalcium phosphate (TTCP), 
as it is the only calcium phosphate with a Ca/P ratio higher than PHA. Therefore, 
TTCP can be combined with one or more calcium phosphates with lower Ca/P 
ratios to obtain PHA or CDHA, avoiding the formation of acids or bases as final 
products. The combinations that have been more studied seek to produce cements 
that adjust to the body temperature in a range of pH around the neutral [34].
The third possible system consists of more than two compounds, including 
calcium phosphates and other salts. For example, a cement proposed by Norian 
Corporation [5] is used where calcium phosphates with a Ca/P ratio lower than 
PHA and CaCO3 are added as an additional source of calcium. The initial configu-
ration process involves the formation of DCPD, later forming dahllite, a carbonated 
hydroxyapatite similar to the bone mineral [5].
Apatitic CPCs appear as a viscous, easily moldable material; however, their 
injection is difficult. Figure 3 shows the microstructure of an apatitic cement after 
setting. The setting time can also be reduced by means of additives such as with the 
introduction of PHA particles. These changes in the composition may lead to an 
Figure 3. 
Microstructure of an apatitic calcium phosphate cement after setting, showing the micro−/nanosize pore 
structure formed by the entanglement of the precipitated crystals [71].
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adjustment time in the range of about 15 minutes. When hardening of the cement 
paste occurs too fast, the hardened cement must be milled to render it viscous again. 
Subsequently, the paste hardens due to the precipitation of PHA.
After implantation, the mechanical properties can be altered. Investigations indi-
cate that the mechanical properties of apatite CPC tend to increase, unlike brushite 
cement, which initially decrease and increase when the bone develops [98, 99].
2.2 Brushite cements
Brushite (DCPD) is an acidic calcium phosphate that has been found in some 
physiological sites, for example, in bones [100]. Unlike hydroxyapatite, brushite 
is metastable under physiological conditions [101] and for this reason reabsorbed 
much faster than CPC apatite; however, there are studies that conclude that DCPD 
in vivo tends to convert to PHA [26]. Some CPCs were designed to provide brushite 
as the final product.
Several combinations of compounds have been proposed for the formation of 
brushite cements; most are β-tricalcium phosphate (β-TCP) and an acid compo-
nent, namely, monocalcium phosphate monohydrate (MCPM) or phosphoric acid 
[102–104].
The reaction leading to the formation of brushite CPCs is an acid–base reaction. 
The brushite paste is acidic during sedimentation because brushite can only precipi-
tate at a pH value below ~6 [105]. The pH of the cement paste tends to change slowly 
toward equilibrium pH [106]. If the slurry contains an excess of basic phase, the 
pH tends to equilibrate by crossing the solubility of the base phase with that of the 
DCPD. The time of stabilization of brushite CPC depends greatly on the solubility 
of the basic phase: the higher the solubility of the basic phase, the faster the defined 
time. For example, hydroxyapatite (HA) + MCPM blends have an adjustment time of 
several minutes. The β-TCP + MCPM mixtures have an adjustment time of 30–60 sec-
onds [107, 108]. However, compounds that inhibit the development of DCPD crystals 
can be added, increasing the settling time of the β-TCP + MCPM mixtures [109]. The 
brushite CPC can initially be very liquid and still be defined within a short period of 
time, unlike the apatite CPC. The brushite CPC is slightly weaker (tensile strength 
of 10 MPa [110] and compressive strength of 60 MPa) than the apatite CPC (tensile 
strength of 16 MPa [111] and compressive strength of 83 MPa [112]). The mechanical 
properties of apatite CPC increase [98], whereas those of brushite CPC decrease [99] 
This latter phenomenon is attributed to the greater solubility of DCPD in relation to 
that of PHA [113]. After a few weeks of implantation, the mechanical properties of 
brushite CPC are promoted by bone growth [99]. Although brushite CPC exhibits 
biocompatible properties, inflammatory reactions have been reported with the 
excessive addition of brushite CPC [114]. Investigations indicate that these reactions 
are due to the transformation of DCPD into PHA [115]. This reaction releases large 
amounts of acid. The transformation of DCPD into PHA can be avoided with the 
addition of magnesium ions to the cement [116]. Unlike apatite CPC, brushite CPC 
cannot be reabsorbed exclusively by osteoclastic activity but also by simple dissolu-
tion. Therefore, brushite CPCs degrade at a faster rate than the apatite CPC.
Although brushite demonstrates a higher solubility rate than the other calcium 
phosphate phases, it is a precursor of the most stable HA phase [117–120]. For this 
reason, DCPD coatings as an initial step to obtaining HA have been widely used. The 
synthesis of HA through precipitation mechanisms results in compacted crystals but 
with sizes difficult to control. Using DCPD as a precursor becomes favorable since it 
is possible to modify the crystal size of the DCPD through homogeneous precipita-
tion and can be converted directly into HA [119]. In environments with a pH > 6–7, 
brushite becomes unstable and becomes the most favorable HA phase [121, 122]. 
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The fact that DCPD is able to be more soluble leads to its use in metal implants as 
a means of increasing the amount of calcium and phosphate ions available in the 
surrounding tissue of the implant to promote increased osseointegration [118].
The biocompatibility of DCPD as a coating has been demonstrated in several cell 
lines as, for example, in pre-osteoblastic macrophages [123, 124] and fibroblastic 
cells [125]. The biocompatibility of DCPD has also been demonstrated when used 
at a cranial defect site in sheep [126], and the formation of new bone was observed 
in the absence of inflammation [81]. A clinical study in humans in 2010 effectively 
used a brushite cement for the repair and increase of pterionic craniotomies, with 
no inflammation occurring [127].
Figure 4 summarizes how the CPCs are classified by type and number of initial 
reagents as well as their final product.
3. Calcium phosphate cement applications
3.1 Drug delivery
The main requirements for a substrate to have potential as a drug carrier are to 
have the ability to incorporate it, to retain it at a specific site, and to distribute it 
progressively over time in surrounding tissues. In addition, it is beneficial that the 
material is injectable and biodegradable [77].
Calcium phosphate cements, in addition to allowing hardening at room or body 
temperature, allow the insertion of various components due to their intrinsic poros-
ity. It is possible to incorporate drugs, biologically active molecules, or even cells 
without their functions being altered by the effect of temperature or even losing 
their activity during the procedure (Figure 5). This change in the CPCs offers new 
properties in addition to the osteoconductive characteristic, namely, to increase 
its capacity for bone regeneration or to support in disorders or pathologies, such as 
bone tumors or osteoporosis [35].
It is necessary to take into account that the performance of the drug delivery 
depends on the structural characteristics such as the specific surface area, perme-
ability, matrix degradation rate, drug solubility, or the interaction itself between the 
matrix and the inserted drug.
Figure 4. 
Classification of calcium phosphate cements, with examples of the most common formulations. From top to 
bottom, the cements are classified by the type of end product (apatite or brushite), a number of components 
in the solid phase (single or multiple), type of setting reaction (hydrolysis or acid–base reaction), setting 
mechanism, and microstructure evolution during setting (adapted from [35]).
Biological Role of Phosphorus
10
The interaction between the drug and the cement matrix is defined by the drug 
insertion procedure. Usually, the drugs are added as a powder to the solid phase or 
dissolved in the liquid part. The method that allows better homogenization of the 
drug in the matrix is in the liquid phase [35].
Another method for inserting the drug into the matrix is by impregnating solid 
beads or granules from the cement with a drug solution. This method continues to 
present benefits compared to other conventional methods even with its impaired 
injection process. The advantages associated with this method are due to the fact 
that the consolidation of the material (dissolution-precipitation reaction) leads to 
the production of hydrated matrices with large specific surface areas that allow the 
loading of drugs and their release mechanism to be favorable [35].
The two drug encapsulation processes differ greatly in the structural properties 
of the matrix. In one method the drug is incorporated in the initial phase together 
with the cement reactants while the matrix is still evolving. Thus, the hardening can 
last for hours or even days until the suspension of particles evolves into a network 
of interlaced crystals. In the other case, if the drug is added to the preconceived 
cement, the matrix structure will always be stable throughout the release process, 
in addition to possible degradation, and therefore the results cannot be extrapolated 
to the previous situation. This highlights the need for the studies to be carried out, 
taking into account the actual conditions of application. The alternative method is 
to incorporate the drug into polymeric microspheres prior to mixing in the cement. 
This procedure has two advantages over the other methods presented. It is possible 
to modify the release kinetics of the drug, and the degradation of the microspheres 
generates an array capable of being more easily reabsorbed and remodeled [35].
The incorporation of drugs can influence the entire mechanism of action of the 
cement and compromise its purpose, changing the fit kinetics, rheological charac-
teristics, and microstructural development. For example, molecules that interact 
with calcium or phosphate ions promote a coprecipitation during the fit or form 
complexes with Ca2+, promoting a delay in precipitation and modifying viscosity, 
set time, and cement properties [72, 129, 130].
Figure 5. 
Scheme about the possible applications of calcium phosphates in the biomolecules and drug delivery (adapted 
from [128]).
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In addition to the influence that the drug has on the cement matrix, it is also 
necessary to take into account the influence of the cement on the stability of the 
drug or bioactive molecule. Due to the dissolution-precipitation process, there is a 
change in the surrounding pH as well as the change in ionic concentrations, which 
may influence the functionality of the drug and its release.
Thus, it is beneficial to study the release of drugs introduced from already 
synthesized cements.
Recently, studies have been developed related to the incorporation of antibiotics, 
as a preventive method of infections resulting from surgeries or as treatment of bone 
infections. In addition to antibiotics, studies with anti-inflammatories, antitumor 
drugs, or hormones have also been disclosed. In another aspect, the incorporation 
of factors that stimulate bone regeneration, such as bone morphogenetic proteins 
(BMP) or transforming growth factors-β (TGF-β), has been studied [77, 131].
3.2 Growth factor addition
Growth factors are a large group of proteins that interact at the cellular level 
[35]. The major families of these proteins are the transforming growth factor-beta 
superfamily responsible for promoting bone regeneration. The BMPs are part of the 
TGF-β superfamily and have been widely used in bone regeneration. It is known to 
play a role as an activating agent in the various biological phenomena responsible 
for bone formation and therefore can accelerate bone growth. These BMPs stand 
out from the other growth factors of the large TGF-βSF group because they are 
osteoinductive. That is, the BMPs act at the level of cell differentiation transforming 
the pluripotential cells into bone-forming cells, aiding in bone formation outside 
the bone tissue [77].
These proteins have been produced at an industrial level with a high level of 
purity; however, it is necessary that their administration is controlled and with 
adequate therapeutic levels as well as adapted to the tissue targets. In fact, it is 
known that the injection of such substances alone cannot induce the formation 
and regeneration of tissues since the protein diffuses very rapidly from the site of 
implantation. Thus, the CPCs present themselves as good substrates and carriers for 
these bioactive molecules, also improving their function as osteoconduction [77].
Studies have shown that the superfamily of growth factors stimulates osteoblast 
proliferation and collagen synthesis in vitro [132] and may increase the size of the 
cortical bone when applied near the periosteum in vivo [133].
This improvement in bone growth, when applied to cement with these mol-
ecules, is due to the adsorption of large doses of rhTGF-β1 on the surface of the 
material [134, 135].
Despite this accumulation of the growth factor to the surface, there is a homog-
enous distribution throughout the cement mass, increasing the time of the release 
of the growth factors while the degradation of the matrix occurs.
Blom et al. showed that the addition of a human recombinant TGF-β1 
(rhTGF-β1) to a CPC in the adjustment phase stimulated the differentiation of pre-
osteoblastic cells using primary mouse bone cells in vitro [136].
In contrast to the kinetics of drug release, the release of these factors becomes 
much slower [137].
It has been determined that in the first days, the release rate of the components is 
higher because the initial release is only of the material present in the surface layer 
that is in contact with the medium. This increase in the rhTGF-β1 release was con-
firmed when the area in contact with the medium occurred by fragmentation. The 
same phenomenon was observed when BMP-2 human recombinant microspheres 
were introduced into the CPC. The release of the factor was quite limited due to 
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the possible physical entrapment of the microparticles inside the porous cement. 
According to the authors, the nanoporosity of CPC not only did not facilitate the 
release of the protein but could also limit it because of the high binding affinity of 
the protein by CPC [138].
Haddad et al. [139] investigated the action of implantation of cement loaded 
with BMP-2 in the bone repair of a critical-sized calvarial vault defect in rabbits. 
Compared with control, an increase in bone formation was observed at 45% after 
12 weeks of implantation.
Other investigations by Seeherman et al. [140, 141] also demonstrated the 
efficiency of these combined systems (BMP-2/cement). For example, these com-
posites accelerated the filling of a bone defect by 40% after approximately 4 months 
of implantation, compared to cement without the protein. This study was done in a 
primate fibula osteotomy [140].
The composite used in the abovementioned study was also used in rabbit bone 
defects. After 4 weeks of implantation, an acceleration of reabsorption was observed 
as well as filling of the defect compared to the base cement. This acceleration led to 
the complete filling of the defect with new bone 8 weeks after the implant.
3.3 Ion addition
To avoid infections resulting from orthopedic surgery, which usually lead to 
bone loss or subsequent removal of the implant, alternatives such as antibiotic 
delivery have been used on the site [142–144]. This transport is usually done using 
poly(methyl methacrylate) (PMMA) or by encapsulating the drug in the CPC 
matrix. PMMA beads have the drawback that they are not resorbable and require 
further surgery to remove them and place new antibiotic-loaded spheres if the goal 
is to prolong the treatment [145–148]. Faced with this drawback, CPCs have been 
widely studied as degradable materials capable of carrying antibiotics [77, 145, 
148–155]. However, there is a risk of creating bacterial resistance due to low doses of 
release [156–158]. Thus, the use of surface functionalization of biomaterials as well 
as the coating of implant surfaces with silver ions has been recurring, conferring 
antibacterial properties [159–163].
The antimicrobial properties of Ag+ ions have been investigated and studied in 
the field of biomedical engineering [164]. It has been found that bacteria hardly 
gain resistance to silver-based products and low concentrations are required to have 
a bactericidal effect [165].
Therefore, both metallic silver and ionic silver were incorporated in several bio-
materials, HA [166–169], and bioactive glasses [164, 170–172]. In both structures, 
silver has relatively low toxicity to human cells [173–176].
Ewald et al. evaluated the antimicrobial properties of silver-loaded bone cements 
as well as their osteoconductive and resorbable properties. The reagents used were 
both α- and β-tricalcium phosphates combined with slightly acidic compounds to 
form HA or brushite cement. This study revealed that it is possible to synthesize 
cements with antimicrobial activity with effects comparable to antibiotic treat-
ments. Figure 6 shows the inhibition of both S. aureus and S. epidermidis cultured 
on the surfaces of the silver-doped cements. Ag-brushite exhibits more antibacterial 
properties than Ag–HA. In addition, in the case of brushite cements, silver ions 
allow the cements to increase in compressive strength by approximately 30% [177].
Several studies have been carried out using silver-doped calcium phosphate 
cements, and the results have been satisfactory, demonstrating inhibitory effect 
against certain bacteria [178].
In addition to silver, other ions have been incorporated into materials composed 
of calcium phosphate. Doping with Co2+ showed proangiogenic effects [179, 180]. 
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Modification with Cu2+ increased the rate of vascularization [181]. The influence 
of the introduction of Co2+, Cu2+, and Cr3+ on calcium phosphate cement was 
investigated, evaluating the material properties, proliferation, and osteogenic 
differentiation of human mesenchymal stem cells in vitro [182]. The Cr3+ and Cu2+ 
ions, in this case with less evidence, had positive effects on osteogenic proliferation 
and differentiation.
Despite all the positive results of this incorporation, the examinations that 
evaluate the osteogenic capacity in vitro are not enough to estimate the clinical 
performance of these materials in the bone graft. Since the balance between bone 
neoformation and material resorption is crucial for successful remodeling, in vitro 
analysis of osteoclast-mediated degradation of materials is a logical next step in 
evaluating material remodeling in vivo [183].
However, it is necessary to take into account the dose that is used in the doping 
process, as investigators have concluded that doses in certain amounts of Cu2+ and 
Co2+ can cause cytotoxic reactions to osteoclasts and progenitors of osteoclasts 
during the initial release of Cu2+ and Co2+, respectively. Cements at lower doses are 
beneficial to bone regeneration since Cu2+ at 18 μM completely inhibits reabsorption 
(but not the formation of osteoclasts), which may be beneficial for patients with 
osteoporosis and imbalance between bone formation and resorption. The addition 
of Cr3+ to brushite cements increases osteoclastic reabsorption and increases the 
viability of osteoprogenitor cells compared to cement without the addition of ions 
[182]. Therefore, Cr3+-doped brushite cements are suggested as a promising new 
material for application in bone regeneration.
3.4 3D printing of CPCs
The 3D printing technique, or additive manufacture (AM), is based on the addi-
tion of layers of powder material producing solid materials with adjustable porosity, 
through a digital geometric model. This method has been the subject of much research 
in the medical field such as in the synthesis of the customized scaffold [184]. In 
addition to the economical and fast production that 3D printing allows, it also allows 
Figure 6. 
Bacterial activity of S. aureus and S. epidermidis on cement surfaces (n = 4) determined by the WST-1-test in 
LB medium [177].
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the manufacture of pieces with high geometric complexity. All these advantages have 
made 3D printing very useful in the field of biomedical and tissue engineering due to 
the ability to replicate the complicated architecture as well as the cellular heterogene-
ity present in tissues and organs. The bone presents itself as an exquisite structure due 
to the existence of a complex compound of minerals and an organic matrix. Taking 
into account this organization, there are several size scales, and it is possible to easily 
reproduce this structure through 3D printing. In addition, 3D printing is suitable for 
producing structures derived from medical images, such as CT scans [185, 186].
Recently, the manufacture of the customized scaffolds of the calcium phosphate 
cements by 3D printing has been described. During printing, highly viscous or 
pasty materials are dispensed through an adjustable dosing nozzle, resulting in the 
deposition of CPC layers on a platform with a liquid or air as a plotting medium. 
After the stabilization of the scaffolds, the water adjustment reaction begins. These 
stabilization and hardening conditions allow the integration of biological molecules 
at specific sites [187].
In this way, it is possible to create scaffolds, based on calcium phosphates, more 
complex with specificities that can promote higher bioactivity or introduce drugs or 
other therapeutic components, taking into account the patients’ needs (Figure 7).
In addition, this technique allows the combination of components (i.e., CPC and 
alginate) to produce structures more resistant to compression and with improved 
toughness compared to pure CPC supports [188].
4. Conclusions and future perspective
Due to its bioactivity, biocompatibility, osteoconductivity, and osteoinductivity, 
calcium phosphate cements present an advantageous option in the field of bone 
tissue engineering, taking into account all the needs that this application demands. 
In addition, it may be used as scaffolds and transport medium for various biological 
molecules such as stem cells, drugs, or growth factors. It is also worth mention-
ing the possibility of producing structures of these cements through 3D printing 
technology, where it is possible to manufacture intrinsically complex biomimetic 
structures due to the degree of precision of this technique.
The possibility of building calcium phosphate cements, involving the incorpora-
tion of several types of cells, growth factors, molecules, or bioactive glasses, allows 
favorable results in the vascularization of bone tissues and, consequently, in bone 
regeneration. This feature, particularly appreciated in large bone regenerations, will 
allow a considerable increase in the use of these structures in clinical applications. 
However, more research is needed to consolidate and understand all the informa-
tion associated with the fundamental mechanisms that promote the development of 
tissue engineering and regenerative medicine.
Figure 7. 
Scheme of the 3D printing system of the calcium phosphate bone cement scaffolds and its advantages due to the 
possibility of improving the settings.
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The success associated with biomaterials has been underestimated maybe 
because they have been used clinically for more than 40 years. However, there is 
still a huge diversity of calcium phosphate-based materials that have not been fully 
investigated.
Acronyms
AM manufacture additive
BMP bone morphogenetic proteins
CDHA calcium-deficient hydroxyapatite
CPCs calcium phosphate cements
DCPA dicalcium phosphate anhydrous
DCPD dicalcium phosphate dihydrate
HA hydroxyapatite
L/P ratio liquid-powder ratio
MCPM monocalcium phosphate monohydrate
PHA precipitated hydroxyapatite
PMMA poly(methyl methacrylate)
TCP tricalcium phosphate
TGF-β transforming growth factors-beta
TTCP tetracalcium phosphate
rhTGF-β1 human recombinant TGF-β1
Author details
Manuel Pedro Fernandes Graça* and Sílvia Rodrigues Gavinho
I3N and Physics Department, University of Aveiro, Aveiro, Portugal
*Address all correspondence to: mpfg@ua.pt
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
16
Biological Role of Phosphorus
References
[1] Brown WE, Chow LC. A new calcium 
phosphate setting cement. Journal of 
Dental Research. 1983;62:672
[2] LeGeros RZ, Chohayeb A, 
Shulman A. Apatitic calcium phosphates: 
Possible dental restorative materials. 
Journal of Dental Research. 1982;61:343
[3] Friedman CD, Costantino PD, 
Takagi S, Chow LC. BoneSource 
hydroxyapatite cement: A novel 
biomaterial for craniofacial skeletal 
tissue engineering and reconstruction. 
Journal of Biomedical Materials 
Research. 1998;43:428-432
[4] Kamerer DB, Hirsch BE,  
Snyderman CH, Costantino P, 
Friedman CD. Hydroxyapatite cement: 
A new method for achieving watertight 
closure in transtemporal surgery. 
The American Journal of Otology. 
1994;15:47-49
[5] Constantz BR, Ison IC, Fulmer MT, 
Poser RD, Smith ST, VanWagoner M, 
et al. Skeletal repair by in in situ 
formation of the mineral phase of bone. 
Science. 1995;267:1796-1799
[6] Horstmann WG, Verheyen CCPM, 
Leemans R. An injectable calcium 
phosphate cement as a bone-graft 
substitute in the treatment of displaced 
lateral tibial plateau fractures. Injury. 
2003;34:141-144
[7] Strauss EJ, Egol KA. The 
management of ankle fractures in the 
elderly. Injury. 2007;38:S2-S9
[8] Liverneaux PA. Osteoporotic distal 
radius curettage—Filling with an 
injectable calcium phosphate cement. 
A cadaveric study. European Journal of 
Orthopaedic Surgery and Traumatology. 
2004;15:1-6
[9] Welch RD, Zhang H, Bronson DG. 
Experimental tibial plateau fractures 
augmented with calcium phosphate 
cement or autologous bone graft. The 
Journal of Bone and Joint Surgery. 
2003;85:222
[10] Aral A, Yalçin S, Karabuda ZC, 
Anil A, Jansen JA, Mutlu Z. Injectable 
calcium phosphate cement as a 
graft material for maxillary sinus 
augmentation: An experimental pilot 
study. Clinical Oral Implants Research. 
2008;19:612-617
[11] Bai B, Jazrawi LM, Kummer FJ, 
Spivak JM. The use of an injectable, 
biodegradable calcium phosphate 
bone substitute for the prophylactic 
augmentation of osteoporotic 
vertebrae and the management of 
vertebral compression fractures. Spine. 
1999;24:1521-1526
[12] Schildhauer T, Bennett A, Wright T, 
Lane J, O’Leary P. Intravertebral body 
reconstruction with an injectable 
in situ-setting carbonated apatite: 
Biomechanical evaluation of a 
minimally invasive technique. Journal of 
Orthopaedic Research. 1999;17:67-72
[13] Maestretti G, Cremer C, 
Otten P, Jakob RP. Prospective study of 
standalone balloon kyphoplasty with 
calcium phosphate cement augmentation 
in traumatic fractures. European Spine 
Journal. 2007;16:601-610
[14] Libicher M, Hillmeier J, Liegibel U, 
Sommer U, Pyerin W, Vetter M, et al. 
Osseous integration of calcium 
phosphate in osteoporotic vertebral 
fractures after kyphoplasty: Initial 
results from a clinical and experimental 
pilot study. Osteoporosis International. 
2006;17:1208-1215
[15] Mermelstein LE, Chow LC,  
Friedman CD, Crisco JJ. The rein-
forcement of cancellous bone screws 
with calcium phosphate cement. Journal 
of Orthopaedic Trauma. 1996;10:15-20
17
Calcium Phosphate Cements in Tissue Engineering
DOI: http://dx.doi.org/10.5772/intechopen.89131
[16] Ooms E, Wolke J, Van der 
Waerden J, Jansen J. Use of injectable 
calcium-phosphate cement for the 
fixation of titanium implants: An 
experimental study in goats. Journal of 
Biomedical Materials Research. Part B, 
Applied Biomaterials. 2003;66:447-456
[17] Takemasa R, Kiyasu K, Tani T, 
Inoue S. Validity of calcium phosphate 
cement vertebroplasty for vertebral 
non-union after osteoporotic fracture 
with middle column involvement. The 
Spine Journal. 2007;7:148S
[18] Tomita S, Kin A, Yazu M, 
Abe M. Biomechanical evaluation 
of kyphoplasty and vertebroplasty 
with calcium phosphate cement in a 
simulated osteoporotic compression 
fracture. Journal of Orthopaedic 
Science. 2003;8:192-197
[19] Lewis G. Injectable bone cements 
for use in vertebroplasty and 
kyphoplasty: State-of-the-art review. 
Journal of Biomedical Materials 
Research. Part B, Applied Biomaterials. 
2006;76:456-468
[20] Ginebra MP, Traykova T, Planell JA.  
Calcium phosphate cements: 
Competitive drug carriers for the 
musculoskeletal system? Biomaterials. 
2006;27:2171-2177
[21] Ginebra MP. Cements as bone repair 
materials. In: Planell JA, editor. Bone 
Repair Biomaterials. Cambridge, UK: 
Woodhead Publishing Limited; 2009. 
pp. 271-308
[22] Canal C, Ginebra MP. Fibre-
reinforced calcium phosphate cements: 
A review. The Journal of the Mechanical 
Behavior of Biomedical Materials. 
2011;4:1658-1671
[23] Ontañón M, Aparicio C, 
Ginebra MP, Planell JA. Structure and 
mechanical properties of bone. In: 
Elices M, editor. Structural Biological 
Materials, Pergamon Material Series. 
Oxford, UK: Elsevier Science Ltd; 2000. 
pp. 31-71
[24] Burstein AH, Reilly DT, Martens M.  
Aging of bone tissue: Mechanical 
properties. The Journal of Bone and 
Joint Surgery. 1976;58A:82-86
[25] Carter DR, Hayes WC. The 
compressive behavior of bone as a 
two-phase porous structure. Clinical 
Orthopaedics and Related Research. 
1977;59A:954-962
[26] Constantz BR, Barr BM, Ison IC, 
Fulmer MT, Baker J, Mckinney LA, 
et al. Histological, chemical, and 
crystallographic analysis of four calcium 
phosphate cements in different rabbit 
osseous sites. Journal of Biomedical 
Materials Research Part B: Applied 
Biomaterials. 1998;43:451-461
[27] Ginebra MP, Fernández E,  
De Maeyer EAP, Verbeeck RMH, 
Boltong MG, Ginebra J, et al. Setting 
reaction and hardening of an apatitic 
calcium phosphate cement. Journal of 
Dental Research. 1997;76(4):905-912
[28] Ginebra MP, Driessens FCM, 
Planell JA. Effect of the particle size 
on the micro and nanostructural 
features of a calcium phosphate cement: 
A kinetic analysis. Biomaterials. 
2004;25:3453-3462
[29] Driessens FCM, Planell JA, 
Boltong MG, Khairoun I, Ginebra MP. 
Osteotransductive bone cements. 
Proceedings of the Institution of 
Mechanical Engineers, Part H: 
Journal of Engineering in Medicine. 
1998;212:427-435
[30] Ishikawa K, Miyamoto Y, Kon M, 
Nagayama M, Asaoka K. Non-decay 
type fast-setting calcium phosphate 
cement: composite with sodium 
alginate. Biomaterials. 1995;16:527-532
[31] Khairoun I, Boltong MG, 
Driessens FC, Planell JA. Effect of 
Biological Role of Phosphorus
18
calcium carbonate on clinical compliance 
of apatitic calcium phosphate bone 
cement. Journal of Biomedical Materials 
Research. 1997;38(4):356-360
[32] Khairoun I, Driessens FCM, 
Boltong MG, Planell JA, Wenz R. 
Addition of cohesion promotors to 
calcium phosphate cements. 
Biomaterials. 1999;20:393-398
[33] Grover LM, Gbureck U, Wright AJ, 
Tremayne M, Barralet JE. Biologically 
mediated resorption of brushite cement 
in vitro. Biomaterials. 2006;27:2178-2185
[34] Ginebra MP. Calcium phosphate 
bone cements. In: Deb S, editor. 
Ortopedic Bone Cements. Boca Raton, 
FL: CRC Press; 2008. pp. 206-230
[35] Ginebra MP, Canal C, Espanol M, 
Pastorino D, Edgar B. Calcium phosphate 
cements as drug delivery materials. 
Advanced Drug Delivery Reviews. 
2012;64:1090-1110
[36] Zhang J, Liu W, Schnitzler V, 
Tancret F, Bouler JM. Calcium phosphate 
cements for bone substitution: 
Chemistry, handling and mechanical 
properties. Acta Biomaterialia. 2014;10: 
1035-1049
[37] Zhang JT, Tancret F, Bouler JM. 
Fabrication and mechanical properties 
of calcium phosphate cements (CPC) 
for bone substitution. Materials Science 
& Engineering. C, Materials for 
Biological Applications. 2011;31:740-747
[38] Guo H, Su JC, Wei J, Kong H, Liu CS. 
Biocompatibility and osteogenicity of 
degradable Ca-deficient hydroxyapatite 
scaffolds from calcium phosphate 
cement for bone tissue engineering. Acta 
Biomaterialia. 2009;5:268-278
[39] Barralet JE, Grover L, Gaunt T, 
Wright AJ, Gibson IR. Preparation 
of macroporous calcium phosphate 
cement tissue engineering scaffold. 
Biomaterials. 2002;23:3063-3072
[40] Takagi S, Chow LC. Formation 
of macropores in calcium phosphate 
cement implants. The Journal of 
Materials Science: Materials in 
Medicine. 2001;12:135-139
[41] Li M, Liu XY, Liu XD, Ge BF, 
Chen KM. Creation of macroporous 
calcium phosphate cements as bone 
substitutes by using genipin-crosslinked 
gelatin microspheres. The Journal 
of Materials Science: Materials in 
Medicine. 2009;20:925-934
[42] Xu H, Quinn JB, Takagi S, Chow LC, 
Eichmiller FC. Strong and macroporous 
calcium phosphate cement: Effects 
of porosity and fiber reinforcement 
on mechanical properties. Journal 
of Biomedical Materials Research. 
2001;57:457-466
[43] Cama G, Barberis F, Botter R, 
Cirillo P, Capurro M, Quarto R, et al. 
Preparation and properties of 
macroporous brushite bone cements. 
Acta Biomaterialia. 2009;5:2161-2168
[44] Félix Lanao RP, Leeuwenburgh SCG, 
Wolke JGC, Jansen JA. In vitro 
degradation rate of apatitic calcium 
phosphate cement with incorporated 
PLGA microspheres. Acta Biomaterialia. 
2011;7:3459-3468
[45] Habraken WJEM, Liao HB, 
Zhang Z, Wolke JGC, Grijpma DW, 
Mikos AG, et al. In vivo degradation of 
calcium phosphate cement incorporated 
into biodegradable microspheres. Acta 
Biomaterialia. 2010;6:2200-2211
[46] Klijn RJ, van den Beucken J, 
Lanao R, Veldhuis G, Leeuwenburgh SC, 
Wolke J, et al. Three different strategies 
to obtain porous calcium phosphate 
cements: Comparison of performance 
in a rat skull bone augmentation model. 
Tissue Engineering. Part A. 2012;18: 
1171-1182
[47] Qi XP, Ye JD. Mechanical and 
rheological properties and injectability 
19
Calcium Phosphate Cements in Tissue Engineering
DOI: http://dx.doi.org/10.5772/intechopen.89131
of calcium phosphate cement 
containing poly (lactic-co-glycolic acid) 
microspheres. Materials Science & 
Engineering. C, Materials for Biological 
Applications. 2009;29:1901-1906
[48] Almirall A, Larrecq G, Delgado JA,  
Martinez S, Planell JA, Ginebra MP.  
Fabrication of low temperature 
macroporous hydroxyapatite scaffolds 
by foaming and hydrolysis of an a-TCP 
paste. Biomaterials. 2004;25:3671-3680
[49] Del Real RP, Wolke J, Vallet-Regi M,  
Jansen JA. A new method to produce  
macropores in calcium phosphate  
cements. Biomaterials. 2002;23: 
3673-3680
[50] Chen WC, Zhou HZ, Tang MH, 
Weir MD, Bao CY, Xu H. Gas-foaming 
calcium phosphate cement scaffold 
encapsulating human umbilical cord 
stem cells. Tissue Engineering. Part A. 
2012;18:816-827
[51] Hesaraki S, Moztarzadeh F, 
Sharifi D. Formation of interconnected 
macropores in apatitic calcium 
phosphate bone cement with the use 
of an effervescent additive. Journal of 
Biomedical Materials Research. Part A. 
2007;83A:80-87
[52] Ginebra M, Delgado J, Harr I,  
Almirall A, Del Valle S, Planell JA. 
Factors affecting the structure and 
properties of an injectable self-setting 
calcium phosphate foam. Journal of 
Biomedical Materials Research. Part A. 
2007;80A:351-361
[53] Bai F, Meng GL, Yuan YA, Liu CS, 
Wang Z, Liu JA. Role of macropore 
size in the mechanical properties and 
in vitro degradation of porous calcium 
phosphate cements. Materials Letters. 
2010;64:2028-2031
[54] Liu CS, Shao HF, Chen FY, 
Zheng HY. Effects of the granularity 
of raw materials on the hydration 
and hardening process of calcium 
phosphate cement. Biomaterials. 
2003;24:4103-4113
[55] TenHuisen KS, Brown PW.  
Formation of calcium-deficient 
hydroxyapatite from α-tricalcium 
phosphate. Biomaterials. 1998;19: 
2209-2217
[56] Bermudez O, Boltong MG, 
Driessens FCM, Planell JA. Development 
of some calcium-phosphate cements 
from combinations of α-TCP, MCPM and 
CaO. The Journal of Materials Science: 
Materials in Medicine. 1994;5:160-163
[57] Yang QZ, Troczynski T, Liu DM. 
Influence of apatite seeds on the 
synthesis of calcium phosphate cement. 
Biomaterials. 2002;23:2751-2760
[58] Tamimi F, Sheikh Z, Barralet J. 
Dicalcium phosphate cements: Brushite 
and monetite. Acta Biomaterialia. 
2012;8:474-487
[59] Sarda S, Fernandez E, Nilsson M, 
Balcells M, Planell JA. Kinetic study 
of citric acid influence on calcium 
phosphate bone cements as water-
reducing agent. Journal of Biomedical 
Materials Research. 2002;61:653-659
[60] Gbureck U, Barralet JE, 
Spatz K, Grover LM, Thull R. Ionic 
modification of calcium phosphate 
cement viscosity. Part I: Hypodermic 
injection and strength improvement 
of apatite cement. Biomaterials. 
2004;25:2187-2195
[61] Barralet JE, Hofmann M, 
Grover LM, Gbureck U. High-strength 
apatitic cement by modification 
with α-hydroxy acid salts. Advanced 
Materials. 2003;15:2091-2094
[62] Barralet JE, Grover LM, Gbureck U. 
Ionic modification of calcium phosphate 
cement viscosity. Part II: Hypodermic 
injection and strength improvement 
of brushite cement. Biomaterials. 
2004;25:2197-2203
Biological Role of Phosphorus
20
[63] Qi XP, Ye JD, Wang YJ. Improved 
injectability and in vitro degradation 
of a calcium phosphate cement 
containing poly(lactide-co-glycolide) 
microspheres. Acta Biomaterialia. 
2008;4:1837-1845
[64] Marino FT, Torres J, Hamdan M, 
Rodriguez CR, Cabarcos EL. Advantages 
of using glycolic acid as a retardant in 
a brushite forming cement. Journal 
of Biomedical Materials Research. 
2007;83B:571-579
[65] Munz D, Fett D. Ceramics: Mechanical 
Properties, Failure Behavior, Materials 
Selection. Germany: Springer; 2001
[66] Munz D. What can we learn 
from r-curve measurements? Journal 
of the American Ceramic Society. 
2007;90:1-15
[67] Ritchie RO. The conflicts between 
strength and toughness. Nature 
Materials. 2011;10:817-822
[68] Launey ME, Ritchie RO. On the 
fracture toughness of advanced materials. 
Advanced Materials. 2009;21:2103-2110
[69] Chow LC, Hirayama S, Takagi S, 
Parry E. Diametral tensile strength 
and compressive strength of a calcium 
phosphate cement: Effect of applied 
pressure. Journal of Biomedical 
Materials Research. 2000;53:511-517
[70] Hofmann MP, Mohammed AR, 
Perrie Y, Gbureck U, Barralet JE. High-
strength resorbable brushite bone 
cement with controlled drug-releasing 
capabilities. Acta Biomaterialia. 
2009;5:43-49
[71] Chow LC. Development of self-
setting calcium phosphate cements. 
Journal of the Ceramic Society 
of Japan (International Edition). 
1991;99:927-936
[72] Ginebra MP, Rilliard A, 
Fernández E, Elvira C, San Román J, 
Planell JA. Mechanical and rheological 
improvement of a calcium phosphate 
cement by the addition of a polymeric 
drug. Journal of Biomedical Materials 
Research. 2001;57:113-118
[73] Driessens FCM, Boltong MG, 
Bermúdez O, Planell JA, Ginebra MP, 
Fernández E. Effective formulations for 
the preparation of calcium phosphate 
bone cements. Journal of Materials 
Science. Materials in Medicine. 
1994;5:164-170
[74] Ginebra MP. Desarrollo y 
caracterización de un cemento óseo 
basado en fosfato tricálcico-α para 
aplicaciones quirúrgicas [PhD thesis]. 
Barcelona, Spain: Universitat Politècnica 
de Catalunya; 1996
[75] Chow LC. Calcium phosphate 
cements: Chemistry, properties, 
and applications. MRS Proceedings. 
1999;599:27
[76] Xu HH, Weir MD, Burguera EF, 
et al. Injectable and macroporous 
calcium phosphate cement scaffold. 
Biomaterials. 2006;27:4279-4287
[77] Ginebra MP, Traykova T, Planell JA. 
Calcium phosphate cements as bone 
drug delivery systems: A review. Journal 
of Controlled Release. 2006;113:102-110
[78] Weir MD, Xu HH. Osteoblastic 
induction on calcium phosphate 
cement-chitosan constructs for 
bone tissue engineering. Journal of 
Biomedical Materials Research. Part A. 
2010;94:223-233
[79] Mestres G, Le Van C, Ginebra MP.  
Silicon-stabilized α-tricalcium 
phosphate and its use in a calcium 
phosphate cement: Characterization 
and cell response. Acta Biomaterialia. 
2012;8:1169-1179
[80] Lanao RPF, Leeuwenburgh SC, 
Wolke JG, et al. Bone response to 
fast-degrading, injectable calcium 
21
Calcium Phosphate Cements in Tissue Engineering
DOI: http://dx.doi.org/10.5772/intechopen.89131
phosphate cements containing 
PLGA microparticles. Biomaterials. 
2011;32:8839-8847
[81] Theiss F, Apelt D, Brand B, et al. 
Biocompatibility and resorption of a 
brushite calcium phosphate cement. 
Biomaterials. 2005;26:4383-4394
[82] Noetzel J, Özer K, Reisshauer 
B-H, et al. Tissue responses to an 
experimental calcium phosphate 
cement and mineral trioxide aggregate 
as materials for furcation perforation 
repair: A histological study in dogs. 
Clinical Oral Investigations. 2006;10:77
[83] Kurashina K, Kurita H, Kotani A, 
Klein CPAT, Groot K. In vivo study 
of calcium phosphate cements: 
Implantation of an α-tricalcium 
phosphate/dicalcium phosphate 
dibasic/tetracalcium phosphate 
monoxide cement paste. Biomaterials. 
1997;18:539-543
[84] Jansen JA, Ruijter JE, Schaeken HG,  
van der Waerden JPC, Planell JA,  
Driessens FCM. Evaluation of 
tricalciumphosphate/hydroxyapatite 
cement for tooth replacement: An 
experimental animal study. Journal 
of Materials Science: Materials in 
Medicine. 1995;6:653-657
[85] Friedman CD, Costantino PD, Takagi S, 
Chow LC. Bonesource hydroxyapatite 
cement: A novel biomaterial for 
cranofacial skeletal tissue engineering 
and reconstruction. Journal of 
Biomedical Materials Research Part B: 
Applied Biomaterials. 1998;43:428-432
[86] Larsson S, Bauer TW. Use of 
injectable calcium phosphate cement 
for fracture fixation: A review. Clinical 
Orthopaedics and Related Research. 
2002;395:23-32
[87] Ooms EM, Wolke JGC, van de 
Heuvel MT, Jeschke B, Jansen JA. 
Histological evaluation of the bone 
response to calcium phosphate cement 
implanted in cortical bone. 
Biomaterials. 2003;24:989-1000
[88] Frankenburg EP, Goldstein SA,  
Bauer TW, Harris SA, Poser RD.  
Biomechanical and histological 
evaluation of a calcium phosphate 
cement. The Journal of Bone and 
Joint Surgery. American Volume. 
1998;80:1112
[89] Apelt D, Theiss F, El-warrak AO, 
Zlinszky K, Bettschart-Wolfisberger R, 
Bohner M, et al. In vivo behavior of 
three different injectable hydraulic 
calcium phosphate cements. 
Biomaterials. 2004;25:1439-1451
[90] Ohura K, Bohner M, Hardouin P,  
Lemaitre J, Pasquier G, Flautre B. 
Resorption of, and bone formation 
from, new betatricalcium phosphate-
monocalcium phosphate cements: An 
in vivo study. Journal of Biomedical 
Materials Research. 1996;30:193-200
[91] Munting E, Mirtchi AA, Lemaitre J.  
Bone repair of defects filled with 
phosphocalcic hydraulic cement: an 
in vivo study. Journal of Materials 
Science. Materials in Medicine. 1993;4: 
337-344
[92] Bohner M, Theiss F, Apelt D, 
Hirsiger W, Houriet R, Rizzoli G, et al. 
Compositional changes of a dicalcium 
phosphate dihydrate cement after 
implantation in sheep. Biomaterials. 
2003;24:3463-3474
[93] Lu J, Descamps M, Dejou J, et al. 
The biodegradation mechanism of 
calcium phosphate biomaterials in 
bone. Journal of Biomedical Materials 
Research. Part A. 2002;63:408-412
[94] Dorozhkin SV. Calcium 
orthophosphate cements and concretes. 
Materials. 2009;2:221-291
[95] Morgan E, Yetkinler D, Constantz B, 
Dauskardt R. Mechanical properties 
of carbonated apatite bone mineral 
Biological Role of Phosphorus
22
substitute: Strength, fracture and 
fatigue behavior. Journal of Materials 
Science. Materials in Medicine. 
1997;8:559-570
[96] Montufar EB, Traykova T, Schacht E, 
Ambrosio L, Santin M, Planell JA, 
et al. Self-hardening calcium deficient 
hydroxyapatite/gelatine foams for 
bone regeneration. Journal of Materials 
Science. Materials in Medicine. 
2010;21:863-869
[97] Fernández E, Gil FJ, Ginebra MP, 
Driessens FCM, Planell JA, Best S. 
Calcium phosphate bone cements for 
clinical applications. Part II: Precipitate 
formation during setting reactions. 
Journal of Materials Science: Materials 
in Medicine. 1999;10:177-183
[98] Miyamoto Y, Ishikawa K, Fukao H, 
Sawada M, Nagagama M, Kon M, et al. 
In vivo setting behaviour of fast-
setting calcium phosphate cement. 
Biomaterials. 1995;16:855-860
[99] Ikenaga M, Hardouin I, 
Lemaitre J, Andrianjatovo H, Flautre B. 
Biomechanical characterization of 
a biodegradable calcium phosphate 
hydraulic cement: A comparison with 
porous biphasic calcium phosphate 
ceramics. Journal of Biomedical 
Materials Research. 1998;40:139-144
[100] Muenzenberg K, Gebhardt M. 
Brushite, octocalcium phosphate, and 
carbonate containing apatite in bone. 
Clinical Orthopaedics and Related 
Research. 1973;90:271-273
[101] Terjesen T. Bone healing after metal 
plate fixation and external fixation 
of the osteotomized rabbit tibia. Acta 
Orthopaedica Scandinavica. 1984;55:69
[102] Lemaitre J, Mirtchi A, Mortier A. 
Calcium phosphate cements for medical 
use: State of the art and perspectives 
of development. Silicates Industriels. 
1987;52:141-146
[103] Mirtchi AA, Lemaitre J, Terao N. 
Calcium phosphate cements: Study 
of the [beta]-tricalcium phosphate–
monocalcium phosphate system. 
Biomaterials. 1989;10:475-480
[104] Bajpai P, Fuchs C, McCullum DE. 
Development of tricalcium phosphate 
ceramic cements. In: Lemons J, editor. 
Quantitative Characterization and 
Performance of Porous Implants for 
Hard Tissue Applications. Philadelphia, 
USA: American Society for Testing 
Materials. 1987. pp. 377-388
[105] Elliott J. Structure and Chemistry 
of the Apatites and Other Calcium 
Orthophosphates. Amsterdam: Elsevier; 
1994
[106] Bohner M, Van Landuyt P, 
Merkle H, Lemaitre J. Composition 
effects on the pH of a hydraulic 
calcium phosphate cement. The Journal 
of Materials Science: Materials in 
Medicine. 1997;8:675-681
[107] Lemaitre J, Mirtchi A, Mortier A. 
Calcium phosphate cements for medical 
use: state of the art and perspectives 
of development. Silicates Industriels. 
1987;9-10:141-6
[108] Bohner M. Proprietes physico-
chimiques et osteogeniques d’un 
biociment hydraulique a base de 
phosphates de calcium [PhD thesis No. 
1171]. Lausanne: Swiss Federal Institute 
of Technology of Lausanne (EPFL); 1993
[109] Bohner M, Van Landuyt P, 
Trophardy G, Merkle H, Lemaitre J. 
Effect of several additives and their 
admixtures on the physico-chemical 
properties of a calcium phosphate 
cement. Journal of Materials Science. 
Materials in Medicine. 2000;11:111-116
[110] Andrianjatovo H, Jose F, Lemaitre J. 
Effect of b-TCP granulometry on setting 
time and strength of calcium phosphate 
hydraulic cements. Journal of Materials 
Science. Materials in Medicine. 
1996;7:34-39
23
Calcium Phosphate Cements in Tissue Engineering
DOI: http://dx.doi.org/10.5772/intechopen.89131
[111] Ishikawa K, Takagi S, Chow L, 
Ishikawa Y, Eanes E, Asaoka K. Behavior 
of a calcium phosphate cement in 
simulated blood plasma in vitro. Dental 
Materials. 1994;10:26-32
[112] Driessens F. Chemistry and 
applied aspects of calcium phosphate 
bone cements. In: Concepts and 
Clinical Applications of Ionic Cements. 
Presented at the 15th European 
Conference on Biomaterials. ESB 99, 
Arcachon, France; 1999
[113] Shadanbaz S, Dias GJ. Calcium 
phosphate coatings on magnesium alloys 
for biomedical applications: A review. 
Acta Biomaterialia. 2012;8:20-30
[114] Hardouin P, Delecourt C, Blary M, 
Van Landuyt I, Lemaitre J, Hardouin L. 
Volume effect on biological properties 
of a calcium phosphate hydraulic 
cement: Experimental study in sheep. 
Bone. 1999;25:35-39
[115] Bohner M. Calcium 
orthophosphates in medicine: From 
ceramics to calcium phosphate cements. 
Injury-International Journal of the Care 
of the Injured. 2000;31:S-D37-47
[116] Bohner M, Matter S. Brushite 
hydraulic cement stabilized with a 
magnesium salt. PCT application PCT/
CH99/00595, Switzerland. 1999
[117] Kumar M, Xie J, Chittur K, Riley C. 
Transformation of modified brushite 
to hydroxyapatite in aqueous solution: 
Effects of potassium substitution. 
Biomaterials. 1999;20:1389-1399
[118] Kumar M, Dasarathy H, Riley C.  
Electrodeposition of brushite 
coatings and their transformation to 
hydroxyapatite in aqueous solutions. 
Journal of Biomedial Materials Research 
Part A. 1999;45:302-310
[119] Redepenning J, Schlessinger T, 
Burnham S, Lippiello L, Miyano J. 
Characterization of electrolytically 
prepared brushite and hydroxyapatite 
coatings on orthopedic alloys. Journal 
of Biomedial Materials Research Part A. 
1996;30:287-294
[120] Xie J, Riley C, Chittur K. Effect of 
albumin on brushite transformation to 
hydroxyapatite. Journal of Biomedical 
Materials Research. 2001;57:357-365
[121] Levinskas G, Neuman W. The 
solubility of bone mineral. I. Solubility 
studies of synthetic hydroxylapatite. 
The Journal of Physical Chemistry. 
1955;59:164-168
[122] Strates B, Neuman W, Levinskas G. 
The solubility of bone mineral. II. 
Precipitation of near-neutral solutions 
of calcium and phosphate. The Journal 
of Physical Chemistry. 1957;61:279-282
[123] Xia Z, Grover L, Huang Y, 
Adamopoulos I, Gbureck U, Triffitt J, 
et al. In vitro biodegradation of three 
brushite calcium phosphate cements by 
a macrophage cell-line. Biomaterials. 
2006;27:4557-4565
[124] Tamimi F, Kumarasami B, 
Doillon C, Gbureck U, Le Nihouannen D, 
Cabarcos E, et al. Brushite–collagen 
composites for bone regeneration. Acta 
Biomaterialia. 2008;4:1315
[125] Klammert U, Reuther T, Jahn C,  
Kraski B, Kbler A, Gbureck U. 
Cytocompatibility of brushite and 
monetite cell culture scaffolds made by 
three-dimensional powder printing. 
Acta Biomaterialia. 2009;5:727
[126] Kuemmerle J, Oberle A, Oechslin C, 
Bohner M, Frei C, Boecken I, et al. 
Assessment of the suitability of a new 
brushite calcium phosphate cement for 
cranioplasty—An experimental study in 
sheep. Journal of Cranio-Maxillo-Facial 
Surgery. 2005;33:37-44
[127] Ji C, Ahn J. Clinical experience 
of the brushite calcium phosphate 
cement for the repair and augmentation 
of surgically induced cranial defects 
Biological Role of Phosphorus
24
following the pterional craniotomy. 
Journal of Korean Neurosurgical 
Association. 2010;47:180
[128] Bose S, Tarafder S. Calcium 
phosphate ceramic systems in growth 
factor and drug delivery for bone 
tissue engineering: A review. Acta 
Biomaterialia. 2012;8:1401-1421
[129] Bigi A, Bracci B, Panzavolta S. 
Effect of added gelatin on the properties 
of calcium phosphate cement. 
Biomaterials. 2004;25:2893-2899
[130] Ratier A, Best S, Freche M, 
Lacout J, Rodriguez F. Behaviour of 
a calcium phosphate bone cement 
containing tetracycline hydrochloride 
or tetracycline complexed with calcium 
ions. Biomaterials. 2001;22:897-901
[131] Nimni ME. Polypeptide growth 
factors: Targeted delivery systems. 
Biomaterials. 1997;18:1201-1225
[132] Centrella M, Massague J, Canalis E. 
Human platelet-derived transforming 
growth factor β stimulates parameters 
of bone growth in fetal rat calvaria. 
Endocrinology. 1986;119:2306-2312
[133] Noda M, Camilliere JJ. In vivo 
stimulation of bone formation 
by transforming growth factor β. 
Endocrynology. 1989;124:2991-2994
[134] Bosch C, Melsen B, Gibbons R, 
Vargervik K. Human recombinant 
transforming growth factor beta 1 in 
healing of calvarial bone defects. 
Journal of Craniofacial Surgery. 
1996;7:300-310
[135] Lind M, Overgaard S, Soballe K, 
Nguyen T, Ongpipattanakul B, Bunger C. 
Transforming growth factor-beta 1 
enhances bone healing to unloaded 
tricalcium phosphate coated implants: 
An experimental study in dogs. 
Journal of Orthopaedic Research. 
1996;14:343-350
[136] Blom EJ, Klein-Nulend J, 
Klein CPAT, Kurashina K, van Waas MAJ, 
Burger EH. Transforming growth 
factor-β1 incorporated during setting 
in calcium phosphate cement stimulates 
bone cell differentiation in vitro. Journal 
of Biomedical Materials Research. 
2000;50:67-74
[137] Blom EJ, Klein-Nulend J, Yin L, van 
Waas MAJ, Burger EH. Transforming 
growth factor-β1 in calcium phosphate 
cement stimulates bone regeneration. 
Journal of Dental Research. 2000;79:255
[138] Ruhe PQ , Hedberg EL, Padron NT, 
Spauwen PH, Jansen JA, Mikos AG. 
rhBMP-2 release from injectable 
poly(DL-lactic-co-glycolic acid)/ 
calcium-phosphate cement composites. 
The Journal of Bone and Joint Surgery. 
2003;85:75-82
[139] Haddad AJ et al. Closure of 
rabbit calvarial critical-sized defects 
using protective composite allogeneic 
and alloplastic bone substitutes. 
The Journal of Craniofacial Surgery. 
2006;17:926-934
[140] Seeherman HJ et al. Recombinant 
human bone morphogenetic protein-2 
delivered in an injectable calcium 
phosphate paste accelerates osteotomy-
site healing in a nonhuman primate 
model. The Journal of Bone and Joint 
Surgery. American Volume. 2004;86-A: 
1961-1972
[141] Seeherman HJ et al. rhBMP-2 
delivered in a calcium phosphate cement 
accelerates bridging of critical-sized 
defects in rabbit radii. The Journal 
of Bone and Joint Surgery. American 
Volume. 2006;88:1553-1565
[142] Ruchholtz S, Tager G, Nast-Kolb D. 
The periprosthetic total hip infection. 
Unfallchirurg. 2004;107:307-317
[143] Harris W, Sledge CB. Total hip 
and total knee replacement (Part II). 
The New England Journal of Medicine. 
1990;323:801-807
25
Calcium Phosphate Cements in Tissue Engineering
DOI: http://dx.doi.org/10.5772/intechopen.89131
[144] Lew DP, Waldvogel FA. Osteo-
myelitis. The Lancet. 2004;364:369-379
[145] Bohner M, Lemaitre J, Van 
Landuyt P, Zambelli PY, Merkle HP, 
Gander B. Gentamicin-loaded hydraulic 
calcium phosphate bone cement 
as antibiotic delivery system. 
Journal of Pharmaceutical Sciences. 
1997;86:565-572
[146] Alt V, Bechert T, Steinrcke P, 
Wagener M, Seidel P, Dingeldein E, 
et al. An in vitro assessment of the 
antibacterial properties and cytotoxicity 
of nanoparticulate silver bone cement. 
Biomaterials. 2004;25:4383-4391
[147] Itokazu M, Wenyi Y, Aoki T,  
Ohara A, Kato N. Synthesis of 
antibiotic-loaded interporous 
hydroxyapatite blocks by vacuum 
method and in vitro drug release 
testing. Biomaterials. 1998;19:817-819
[148] Penner MJ, Masri BA, Duncan CP. 
Elution characteristics of vancomycin 
and tobramycin combined in 
acrylic bone-cement. The Journal of 
Arthroplasty. 1996;11:939-944
[149] Dion A, Langman M, 
Hall G, Filiaggi M. Vancomycin release 
behaviour from amorphous calcium 
polyphosphate matrices intended for 
osteomyelitis treatment. Biomaterials. 
2005;26:7276-7285
[150] Jiang PJ, Patel S, Gbureck U, 
Grover LM. A comparison of the efficacy 
of hydroxyapatite based cements and 
gels as drug delivery matrices. Key 
Engineering Materials. 2008;93:327-330
[151] Frutos P, Pena E, Frutos G,  
Barrales-Rienda JM. Release of 
gentamicin sulphate from modified 
commercial bone cement. Effect 
of (2-hydroxyethyl methacrylate) 
comonomer and poly(N-vinyl-2-
pyrrolidone) additive on release 
mechanism and kinetics. Biomaterials. 
2002;23:3787-3797
[152] Schnieders J, Gbureck U, 
Thull R, Kissel T. Controlled release of 
gentamicin from calcium phosphate–
poly(lactic acid-co-glycolic acid) 
composite bone cement. Biomaterials. 
2006;27:4239-4249
[153] Anttipoika I, Josefsson G, 
Konttinen Y, Lidgren L, Santavirta S, 
Sanzen L. Hip-arthroplasty infection—
Current concepts. Acta Orthopaedica 
Scandinavica. 1990;61:163-169
[154] Barralet JE, Aldred S, 
Wright AJ, Coombes AGA. In vitro 
behavior of albumin-loaded carbonate 
hydroxyapatite gel. Journal of 
Biomedical Materials Research. 
2002;60:360-367
[155] Gitelis S, Brebach GT. The 
treatment of chronic osteomyelitis with 
a biodegradable antibiotic-impregnated 
implant. Journal of Orthopaedic 
Surgery. 2002;10:53-60
[156] Hendriks JGE, van Horn JR, van 
der Mei HC, Busscher HJ. Backgrounds 
of antibiotic-loaded bone cement 
and prosthesis-related infection. 
Biomaterials. 2004;25:545-556
[157] Pitto RP, Spika IA. Antibiotic-
loaded bone cement spacers in 
two-stage management of infected 
total knee arthroplasty, International 
Orthopaedics. 2004;28:129-133
[158] Durbhakula SM, Czajka J,  
Fuchs MD, Uhl RL. Spacer 
endoprosthesis for the treatment of 
infected total hip arthroplasty. The 
Journal of Arthroplasty. 2004;19:760-767
[159] Ewald A, Gluckermann SK, 
Thull R, Gbureck U. Antimicrobial 
titanium/silver PVD coatings on 
titanium, BioMedical Engineering 
Online. 2006;5:22
[160] Yorganci K, Krepel C, Weigelt JA, 
Edmiston CE. Activity of antibacterial 
impregnated central venous catheters 
Biological Role of Phosphorus
26
against Klebsiella pneumonia, Intensive 
Care Medicine. 2002;28:438-442
[161] Davenport K, Keeley FX. Evidence 
for the use of silver-alloy-coated 
urethral catheters. The Journal of 
Hospital Infection. 2005;60:298-303
[162] Cook G, Costerton JW,  
Darouiche RO. Direct confocal 
microscopy studies of the bacterial 
colonization in vitro of a silver-
coated heart valve sewing cuff. The 
International Journal of Antimicrobial 
Agents. 2000;13:169-173
[163] Boswald M, Lugauer S, Regenfus A, 
Braun GG, Martus P, Geis C, et al. 
Reduced rates of catheter-associated 
infection by use of a new silver-
impregnated central venous catheter. 
Infection. 1999;27:56-60
[164] Blaker JJ, Nazhat SN, Boccaccini AR. 
Development and characterisation of 
silver-doped bioactive glass-coated 
sutures for tissue engineering and wound 
healing applications. Biomaterials. 
2003;25:1319-1329
[165] Clement JL, Jarrett PS. Anti-
bacterial silver. Metal-Based Drugs. 
1994;1:467-482
[166] Mahabole M, Aiyer R, 
Ramakrishna C, Sreedhar B, Khairnar R. 
Synthesis, characterization and gas 
sensing property of hydroxyapatite 
ceramic. The Bulletin of Materials 
Science. 2005;28:535-545
[167] Kim TN, Feng QL, Kim JO, Wu J, 
Wang H, Chen GC, et al. Antimicrobial 
effects of metal ions (Ag+, Cu2+, Zn2+) 
in hydroxyapatite. Journal of Materials 
Science. Materials in Medicine. 1998;9: 
129-134
[168] Chen W, Oh S, Ong AP, Oh N, 
Liu Y, Courtney HS, et al. Antibacterial 
and osteogenic properties of silver-
containing hydroxyapatite coatings 
produced using a sol gel process. Journal 
of Biomedical Materials Research. 
Part A. 2007;82:899-906
[169] Chen W, Liu Y, Courtney HS,  
Bettenga M, Agrawal CM, 
Bumgardner JD, et al. In vitro anti-
bacterial and biological properties 
of magnetron co-sputtered silver-
containing hydroxyapatite coating. 
Biomaterials. 2006;27:5512-5517
[170] Clupper DC, Hench LL. Bioactive 
response of Ag-doped tape cast 
bioglass-45S5 following heat treatment. 
Journal of Materials Science. Materials 
in Medicine. 2001;12:917-921
[171] Sharma VK, Yngard RA, Lin Y. 
Silver nanoparticles: green synthesis and 
their antimicrobial activities. Advances 
in Colloid and Interface Science. 
2009;145:83-96
[172] Ciceo Lucacel R, Hulpus AO,  
Simon V, Ardelean I. Structural 
characterization of phosphate glasses 
doped with silver. Journal of Non-
Crystalline Solids. 2009;355:425-429
[173] Hollinger MA. Toxicological 
aspects of topical silver 
pharmaceuticals. Critical Reviews in 
Toxicology. 1996;26:255-260
[174] Faust RA. Toxicity Summary for 
Silver, Prepared for the Oak Ridge 
Reservation Environmental Restoration 
Programme. Oak Ridge National 
Laboratory, US Department of Energy; 
1992. Available from: http://rais.ornl.
gov/tox/profiles/silver_c_V1.html 
[Accessed 19 August 2019]
[175] Berger TJ, Spadaro JA, Chapin SE, 
Becher RO. Electrically generated silver 
ions: quantitative effects on bacterial 
and mammalian cells. Antimicrobial 
Agents and Chemotherapy. 
1976;9:357-358
[176] Williams RL, Doherty PJ, 
Vince DG, Grashoff GJ, Williams DF. 
The biocompatibility of silver. Critical 
27
Calcium Phosphate Cements in Tissue Engineering
DOI: http://dx.doi.org/10.5772/intechopen.89131
Reviews in Biocompatibility. 
1989;5:221-223
[177] Ewald A, Hösel D, Patel S, 
Grover LM, Jake E, Barralet JE, et al. 
Silver-doped calcium phosphate 
cements with antimicrobial activity. 
Acta Biomaterialia. 2011;7:4064-4070
[178] Rau JV, Fosca M, Graziani V, 
Egorov AA, Zobkov V, Fedotov A, et al. 
Silver-doped calcium phosphate bone 
cements with antibacterial properties. 
Journal of Functional Biomaterials. 
2016;7:10
[179] Kulanthaivel S, Roy B, Agarwal T, 
Giri S, Pramanik K, Pal K, et al. Cobalt 
doped proangiogenic hydroxyapatite 
for bone tissue engineering application. 
Materials Science & Engineering. C, 
Materials for Biological Applications. 
2016;58:648-658
[180] Birgani ZT, Gharraee N, 
Malhotra A, van Blitterswijk CA, 
Habibovic P. Combinatorial 
incorporation of fluoride and 
cobalt ions into calcium phosphates 
to stimulate osteogenesis and 
angiogenesis. Biomedical Materials 
(Bristol, England). 2016;11:015020
[181] Barralet J, Gbureck U, 
Habibovic P, Vorndran E, Gerard C, 
Doillon CJ. Angiogenesis in calcium 
phosphate scaffolds by inorganic copper 
ion release. Tissue Engineering. Part A. 
2009;15:1601-1609
[182] Schamel M, Bernhardt A, Quade M, 
Wuerkner C, Gbureck U, Moseke C, 
et al. Cu2+, Co2+ and Cr3+ doping of a 
calcium phosphate cement influences 
materials properties and response of 
human mesenchymal stromal cells. 
Materials Science and Engineering: C. 
2017;73:99-110
[183] Bernhardt A, Schamel M, 
Gbureck U, Gelinsky M. Osteoclastic 
differentiation and resorption is 
modulated by bioactive metal ions Co2+, 
Cu2+ and Cr3+ incorporated into calcium 
phosphate bone cements. PLoS One. 
2017;12:e0182109
[184] Bergmanna C, Lindnera M, 
Zhangb W, Koczura K, Kirstena A, 
Telleb R, et al. 3D printing of bone 
substitute implants using calcium 
phosphate and bioactive glasses. Journal 
of the European Ceramic Society. 
2010;30:2563-2567
[185] Trombetta R, Inzana J, Schwarz E, 
Kates S, Awad H. 3D printing of calcium 
phosphate ceramics for bone tissue 
engineering and drug delivery. Annals of 
Biomedical Engineering. 2017;45:23-44
[186] Ngo T, Kashani A, Imbalzano G,  
Nguyena K, Hui D. Additive 
manufacturing (3D printing): A review 
of materials, methods, applications 
and challenges. Composites Part B: 
Engineering. 2018;143:172-196
[187] Akkinenia A, Luoa Y,  
Schumacher M, Nies B, Lode A, 
Gelinsky M. 3D plotting of growth 
factor loaded calcium phosphate 
cement scaffolds. Acta Biomaterialia. 
2015;27:264-274
[188] Luo Y, Lode A, Sonntag F, Nies B, 
Gelinsky M. Well-ordered biphasic 
calcium phosphate–alginate scaffolds 
fabricated by multi-channel 3D plotting 
under mild conditions. Journal of 
Materials Chemistry B. 2013;1:4088
